Canada’s initiative to construct a $267-million medical countermeasures laboratory in Winnipeg is a crucial move in preparing for future pandemics, according to experts. However, they caution that the facility may encounter significant obstacles in terms of securing long-term funding, staffing, and governance.
The federal government recently awarded a $10.2-million contract for the design of the facility, which is scheduled to be operational by 2033 adjacent to Winnipeg’s National Microbiology Laboratory (NML). While the lab’s goal is to address the critical need for testing early-stage vaccines, therapeutics, and diagnostic tools, health experts emphasize that sustained investments in skilled personnel are essential for its success.
Dr. Joanne Liu, a physician and professor at McGill University’s School of Population and Global Health, emphasized the importance of having the necessary human resources to establish a world-class center alongside the physical infrastructure. She underscored the need for a commitment to effective countermeasures beyond just the construction of a building.
The new facility aims to enhance Canada’s capacity for preclinical trials, providing dedicated space for laboratory and animal testing within the country’s research and development pipeline. Currently, space limitations at the NML sometimes require repurposing facilities meant for high-risk pathogen research for preclinical testing purposes.
Industry and academic partners may have access to the laboratory spaces, subject to appropriate agreements and screenings, according to NML’s chief operating officer, Steven Guercio. The lack of local cleanrooms in Canada has hindered university researchers from progressing vaccine discoveries to early human safety trials, as noted by Keith Fowke, scientific director at the Canadian Institutes of Health Research’s infections facility in Winnipeg.
Experts, like Gary Kobinger, stress the critical need for long-term stability and funding commitments to advance countermeasure products over the following years. Ensuring sustained funding during non-crisis periods is essential for the success of pandemic research initiatives, according to McGill’s Liu.
Concerns about governance risks were raised, with Kobinger cautioning against government-led management of the countermeasures lab due to potential bureaucratic challenges. He cited past instances, such as Canada’s handling of the Ebola vaccine development, to highlight the importance of effective governance and funding mechanisms in research initiatives.
While the Public Health Agency of Canada (PHAC) emphasized ongoing funding to enhance medical countermeasures capacity and preclinical research, experts stress the necessity of a comprehensive approach that includes long-term funding, talent retention, and effective governance to ensure the success of such critical initiatives.
